POLXF — Polydex Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $6.82m
- $6.03m
- $4.86m
Annual income statement for Polydex Pharmaceuticals, fiscal year end - January 31st, USD millions except per share, conversion factor applied.
2018 January 31st | 2019 January 31st | 2020 January 31st | 2021 January 31st | 2023 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Preliminary |
| Revenue | |||||
| Total Revenue | 5.28 | 4.94 | 5.14 | 4.86 | 4.4 |
| Cost of Revenue | |||||
| Gross Profit | 1.3 | 0.928 | 1.04 | 0.97 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.8 | 4.77 | 4.89 | 4.65 | — |
| Operating Profit | 0.482 | 0.17 | 0.252 | 0.21 | — |
| Net Income Before Taxes | 0.482 | 0.17 | 0.252 | 0.21 | — |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.448 | 0.231 | 0.251 | 0.212 | — |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.448 | 0.231 | 0.251 | 0.212 | — |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.448 | 0.231 | 0.251 | 0.212 | — |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.129 | 0.067 | 0.088 | 0.062 | — |